Compare ATYR & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATYR | CSBR |
|---|---|---|
| Founded | 2005 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.2M | 90.0M |
| IPO Year | 2015 | 1986 |
| Metric | ATYR | CSBR |
|---|---|---|
| Price | $0.73 | $6.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $8.75 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 2.0M | 23.1K |
| Earning Date | 11-06-2025 | 12-15-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.17 |
| Revenue | $190,000.00 | ★ $58,424,000.00 |
| Revenue This Year | N/A | $4.84 |
| Revenue Next Year | $18,728.88 | $11.51 |
| P/E Ratio | ★ N/A | $40.00 |
| Revenue Growth | N/A | ★ 9.06 |
| 52 Week Low | $0.64 | $5.59 |
| 52 Week High | $7.29 | $11.99 |
| Indicator | ATYR | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 42.99 | 50.09 |
| Support Level | $0.70 | $6.74 |
| Resistance Level | $0.76 | $7.39 |
| Average True Range (ATR) | 0.04 | 0.57 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 32.21 | 30.09 |
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.